Imidazopyrizine syk inhibitors

US8748607B2 · kind B2 · utility

Assignee

• GILEAD CONNECTICUT, INC. · US

Inventors

• Scott A. Mitchell · East Haven, US
• Kevin S. Currie · North Branford, US
• Peter A. Blomgren · Issaquah, US
• Jeffrey E. Kropf · Branford, US
• Seung H. Lee · Sammamish, US
• Jianjun Xu · Bellevue, US
• Douglas G. Stafford · Niskayuna, US
• James P. Harding · Loudonville, US
• Antonio J.M. BARBOSA · Middlebury, US
• Zhongdong Zhao · Guilford, US
• David M. Armistead · Maynard, US
• Soumya Mitra · Liverpool, US

Key dates

• Filing date: Apr 23, 2013
• Grant date: Jun 10, 2014
• Expiry date: Apr 23, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/91205
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Certain imidazopyrazines having the structure of formula (I):or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.